View Older Stories View More Recent Stories

Oct 13, 2020 06:30AM ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference
Sep 22, 2020 06:30AM ProMIS Neurosciences to develop multivalent vaccine for Alzheimer’s disease
Sep 10, 2020 06:30AM ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference
Aug 13, 2020 06:30AM ProMIS Neurosciences Announces Second Quarter 2020 Results
Jul 9, 2020 06:30AM ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer’s disease
Jun 24, 2020 06:30AM ProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders
Jun 17, 2020 06:30AM ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19
May 28, 2020 06:30AM ProMIS Neurosciences and collaborative team receive Supercluster Award supporting avoidance of future pandemics by new strains of the COVID-19 virus
May 20, 2020 06:30AM ProMIS Neurosciences Chairman’s Update details new programs from expanded use of novel technology platform
May 19, 2020 06:30AM ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays
May 13, 2020 06:30AM ProMIS Neurosciences Announces First Quarter 2020 Results
May 12, 2020 06:30AM ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test
May 6, 2020 06:30AM ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS
Apr 30, 2020 06:30AM ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases
Apr 22, 2020 02:43PM ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing
Apr 15, 2020 06:30AM ProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity
Apr 9, 2020 06:30AM Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates
Apr 7, 2020 06:30AM ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020
Mar 24, 2020 06:30AM PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING
Mar 18, 2020 06:30AM ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results
Feb 26, 2020 06:30AM ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease
Feb 25, 2020 06:30AM ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants
Feb 11, 2020 06:30AM ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference
Feb 6, 2020 06:30AM ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference
Feb 6, 2020 06:30AM ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference
Jan 29, 2020 06:30AM ProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020
Jan 15, 2020 06:30AM ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advisory Board
Jan 9, 2020 06:30AM ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum
Jan 8, 2020 06:30AM ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020
Dec 31, 2019 01:54PM ProMIS Neurosciences Completes Second Closing of Private Placement
Dec 10, 2019 07:30AM ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news
Dec 5, 2019 12:50PM Aducanumab is good; next generation Alzheimer’s disease therapies will be better
Nov 14, 2019 07:30AM ProMIS Neurosciences Announces Third Quarter 2019 Results
Nov 7, 2019 07:30AM ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
Oct 24, 2019 03:00AM ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
Oct 23, 2019 09:49AM ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
Oct 17, 2019 07:30AM ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
Oct 8, 2019 07:30AM ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
Sep 16, 2019 07:30AM ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit
Sep 3, 2019 07:30AM ProMIS Neurosciences to Present at HC Wainwright Investment Conference
Aug 27, 2019 07:30AM ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board
Aug 13, 2019 07:30AM ProMIS Neurosciences Announces Second Quarter 2019 Results
Jul 18, 2019 03:00PM ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019
Jul 10, 2019 07:30AM ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference
Jul 9, 2019 07:30AM ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports
Jun 27, 2019 07:30AM ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
Jun 27, 2019 07:30AM ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
Jun 19, 2019 07:30AM ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
Jun 5, 2019 07:30AM ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference
May 29, 2019 07:30AM ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases
View More Recent Stories View Older Stories